Valuation: Wockhardt Limited

Market Cap 306B 3.21B 2.75B 2.58B 2.36B 4.45B 4.47B 30.57B 11.85B 154B 12.04B 11.78B 511B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 321B 3.37B 2.89B 2.71B 2.48B 4.68B 4.7B 32.12B 12.45B 162B 12.65B 12.38B 537B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day-0.92%
1 week+3.07%
Current month-3.96%
1 month+0.91%
3 months+10.70%
6 months+38.02%
Current year+30.14%
1 week 1,825
Extreme 1825
1,932.3
1 month 1,814.4
Extreme 1814.4
2,067.7
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-0.92%+3.07%+28.02%+717.95% 3.24B
-1.17%-0.03%+18.70%+70.05% 48.37B
+0.45%+1.82%+55.52%+123.59% 39.88B
-1.36%-1.36%-11.21%+14.14% 12.05B
+2.27%+4.12%+16.41%+81.30% 11.77B
+0.19%0.00%+30.98%+150.00% 9.19B
-0.45%+3.26%+24.53%+45.36% 7.87B
-0.16%+1.00%+54.03%-10.97% 7.25B
+1.60%+8.54%+25.00%+217.84% 7.1B
+0.95%-8.22%-39.88%+16.67% 5.26B
Average +0.13%+0.83%+20.21%+142.59% 15.2B
Weighted average by Cap. -0.13%+1.19%+27.01%+99.08%

Financials

2025 2026
Net sales 30.35B 318M 273M 256M 234M 442M 444M 3.03B 1.18B 15.31B 1.19B 1.17B 50.71B 34.62B 363M 312M 292M 267M 504M 506M 3.46B 1.34B 17.47B 1.36B 1.33B 57.85B
Net income -470M -4.93M -4.23M -3.97M -3.63M -6.84M -6.88M -46.98M -18.21M -237M -18.5M -18.1M -785M 2.13B 22.33M 19.17M 17.99M 16.43M 31.01M 31.16M 213M 82.51M 1.07B 83.85M 82.03M 3.56B
Net Debt 14.33B 150M 129M 121M 111M 209M 210M 1.43B 555M 7.23B 564M 552M 23.94B 15.53B 163M 140M 131M 120M 226M 227M 1.55B 602M 7.83B 611M 598M 25.95B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
26-08-26 ₹1,882.10 -0.92% 310,259
26-08-25 ₹1,899.60 -0.07% 241,579
26-08-24 ₹1,901.00 +0.78% 306,988
26-08-21 ₹1,886.30 +3.04% 559,221
26-08-20 ₹1,830.60 +0.25% 258,015
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock